⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CSTL News
Castle Biosciences, Inc. Common Stock
Contract Research Organization (CRO) Services Market worth $140.32 billion by 2031 | MarketsandMarkets™
prnewswire.com
IQV
LH
TMO
CSTL
Inovação brasileira em IA e governança de dados ganham destaque no InterSystems READY 2026
businesswire.com
CSTL
Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS
prnewswire.com
CSTL
Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year
prnewswire.com
CSTL
Centri Announces Panel Topics and Featured Programming for Second Annual Capital Conference at Nasdaq on April 14
accessnewswire.com
NDAQ
DFIN
PTGX
STRL
TNDM
AXSM
CSTL
CYTK
GILD
INSM
KODK
NBIX
OCGN
REGN
SRPT
VRTX
XBIT
AMZN
GOOGL
MSFT
NVDA
IBM
ORGN
BWEN
CCJ
EXC
NEE
SO
UTL
XOM
BALY
OXY
PBF
CHRD
AX
BAC
MAXN
PHIO
KZR
SMX
DUOT
COIN
EHTH
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
prnewswire.com
CSTL
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
globenewswire.com
CSTL
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
globenewswire.com
CSTL
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB
globenewswire.com
CSTL
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
globenewswire.com
CSTL